An inflammatory bowel illness (IBD) called Crohn’s disease may be caused by processes of aberrant immune cell action that a group of scientists has identified.

Abdominal discomfort, diarrhea, weight loss, anemia, and exhaustion are some of the symptoms of Crohn’s disease, which is characterized by chronic inflammation of the gastrointestinal (GI) tract.

Gamma delta T cell receptors (gamma delta IELs) are expressed by intraepithelial lymphocytes, white blood cells in the GI tract that serve as monitoring for the intestinal barrier and prevent infection. Patients with active Crohn’s disease often have lower gamma delta IELs. The study is the first to demonstrate that gamma delta IELs are essential for preserving a balance between pro-inflammatory and regulatory immune responses, and that these cells are compromised during the development and course of chronic inflammation in the lower small intestine, according to a research team headed by Mount Sinai.

Gamma delta IELs decreased in patients with active IBD, according to earlier research evaluating patient biopsies. Karen Edelblum, Associate Professor of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai, said that it was unclear whether the loss of these cells was a cause or an effect of the illness.

In a mouse model of Crohn’s disease-like ileitis, the results, which were published in Science Immunology, now demonstrate that gamma delta IELs are significantly reduced weeks before clinical or histological signs of illness.

Additionally, according to Edelblum, “we were able to generate a timeline of events leading to the dysregulation of gamma delta IELs that mirrored findings from prior studies in patients with IBD.”

According to the researchers, gamma delta IEL loss may serve as a prognostic biomarker for recurrence of the illness or patient response to therapy. Future treatments that improve gamma delta IEL activity may also provide a fresh approach to keeping IBD patients in remission or halting the progression of the illness in vulnerable people.